The challenge of eradicating leukemia in patients with acute myelogenous leukemia (AML)
after initial cytoreduction has motivated modern efforts to combine synergistic active …

Two articles in this week's issue focus on the use of ipilimumab and decitabine for patients
with myelodysplasia (MDS) and acute myeloid leukemia (AML) before and after …

Background: CTLA-4 blockade with ipilimumab (IPI) has modest activity in hematologic
malignancies relapsed post allogeneic hematopoietic cell transplantation (allo-HCT)(Davids …

Background: The powerful" graft versus leukemia" effect thought partly responsible for the
therapeutic effect of allogeneic hematopoietic stem cell transplantation in reducing relapse …

Background The powerful 'graft versus leukemia'effect thought partly responsible for the
therapeutic effect of allogeneic hematopoietic cell transplantation in acute myeloid leukemia …

Preclinical models have shown that blocking PD-1/PD-L1 pathways enhances antileukemic
responses. Azacitidine upregulates PD-1 and IFNγ signaling. We therefore conducted this …

Background A recent breakthrough therapy combining the BCL‐2 inhibitor venetoclax with
hypomethylating agents (HMAs) targeting DNA methyltransferase has improved outcomes …

A randomized study of decitabine versus conventional care for maintenance therapy in
patients with acute myeloid leukemia in complete remission | Leukemia Skip to main …

Background: Azacitidine is commonly used in the treatment of relapsed acute myeloid
leukemia (AML) and myelodysplastic syndrome (MDS) after allogeneic hematopoietic stem …

Acute myeloid leukemia (AML) remains a difficult disease to treat disease. In a phase 2
clinical trial in patients with relapsed/refractory AML, combining the hypomethylating agent …